<SEC-DOCUMENT>0001140361-24-017376.txt : 20240402
<SEC-HEADER>0001140361-24-017376.hdr.sgml : 20240402
<ACCEPTANCE-DATETIME>20240402210039
ACCESSION NUMBER:		0001140361-24-017376
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240402
DATE AS OF CHANGE:		20240402

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Grossman Adam S
		CENTRAL INDEX KEY:			0001542517
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		24816638

	MAIL ADDRESS:	
		STREET 1:		65 COMMERCE WAY
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-03-31</periodOfReport>

    <issuer>
        <issuerCik>0001368514</issuerCik>
        <issuerName>ADMA BIOLOGICS, INC.</issuerName>
        <issuerTradingSymbol>ADMA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001542517</rptOwnerCik>
            <rptOwnerName>Grossman Adam S</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADMA BIOLOGICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>465 STATE ROUTE 17</rptOwnerStreet2>
            <rptOwnerCity>RAMSEY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07446</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <officerTitle>President,CEO, and Interim CFO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-03-31</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>21752</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>6.6</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2651475</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1143426</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F5"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>580957</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F6"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.</footnote>
        <footnote id="F2">Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;</footnote>
        <footnote id="F3">(continued from footnote 2) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the &quot;Time-Based RSUs&quot;) which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;</footnote>
        <footnote id="F4">(continued from footnote 3) and (vi) 1,297,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.</footnote>
        <footnote id="F5">These shares are owned by Areth, LLC (&quot;Areth&quot;). The reporting person is a control person of Areth.</footnote>
        <footnote id="F6">These shares are owned by Hariden, LLC (&quot;Hariden&quot;). The reporting person is the managing member of Hariden.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact</signatureName>
        <signatureDate>2024-04-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ef20025805_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 24</font><br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> </font><br>
      <div style="text-align: center; font-weight: bold;">LIMITED POWER OF ATTORNEY</div>
      <div style="text-align: center; font-weight: bold;">FOR SECTION 16(a) REPORTING</div>
      <div>&#160; <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Michael A. Goldstein, Senior Director, General
        Counsel, of ADMA Biologics, Inc. (the &#8220;Company&#8221;) as the undersigned&#8217;s true and lawful attorney-in-fact (the &#8220;Attorney-in Fact&#8221;), with full power of substitution and resubstitution, with the power to act alone for the undersigned and in the
        undersigned&#8217;s name, place and stead, in any and all capacities to:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;prepare, execute and submit to the Securities and
          Exchange Commission (&#8220;SEC&#8221;), any national securities exchange and the Company any and all reports (including any amendment thereto) of the undersigned required or considered advisable under Section 16(a) of the Securities Exchange Act of 1934
          (the &#8220;Exchange Act&#8221;), and the rules and regulations thereunder, with respect to the equity securities of the Company, including Form 3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial
          Ownership), and Form 5 (Annual Statement of Changes in Beneficial Ownership); and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;seek or obtain, as the undersigned&#8217;s representative
          and on the undersigned&#8217;s behalf, information regarding transactions in the Company&#8217;s equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned
          hereby authorizes any such third party to release any such information to the Attorney-in-Fact.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The undersigned acknowledges that:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney authorizes, but does
          not require, the Attorney-in-Fact to act at his discretion on information provided to such Attorney-in-Fact without independent verification of such information;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any documents prepared and/or executed by the
          Attorney-in-Fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his discretion, deems necessary or desirable;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;neither the Company nor the Attorney-in-Fact assumes
          any liability for the undersigned&#8217;s responsibility to comply with the requirements of Section 16 of the Exchange Act, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for
          disgorgement of profits under Section 16(b) of the Exchange Act; and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney does not relieve the
          undersigned from responsibility for compliance with the undersigned&#8217;s obligations under Section 16 of the Exchange Act, including, without, limitation, the reporting requirements under Section 16(a) of the Exchange Act.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary
        or convenient to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his substitute or substitutes, shall
        lawfully do or cause to be done by authority of this Limited Power of Attorney.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with
        respect to the undersigned&#8217;s holdings of and transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Limited Power of Attorney shall be governed by and construed in accordance the laws of the State of Delaware without regard to the laws that
        might otherwise govern under applicable principles of conflicts of laws thereof.</div>
      <div>&#160;</div>
      <div style="text-align: left; text-indent: 36pt;">IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of<br>
      </div>
      <div style="text-align: left; text-indent: 36pt;"> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z03d4116bda954d58b07cd41b77e454fa" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>March 28,2024</div>
              </td>
              <td style="width: 89%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>

        </table>
        &#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z64ea9c5deff44a9e94c8d5bd6857a5b1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 30%; vertical-align: top; padding-bottom: 2px;">
                <div><br>
                </div>
              </td>
              <td style="width: 12%; vertical-align: top; padding-bottom: 2px;">&#160;Signature:</td>
              <td style="width: 17%; vertical-align: top; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div>/s/ Adam S. Grossman</div>
              </td>
              <td style="width: 41%; vertical-align: top; padding-bottom: 2px;"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div><br>
                </div>
              </td>
              <td style="width: 12%; vertical-align: top;">&#160;Print Name:</td>
              <td style="vertical-align: top;" colspan="2">
                <div>Adam S. Grossman</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left;"> <br>
        </div>
        <div style="text-align: left;"> <br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
